Duke University — COVID-19 Antiviral Studies (Timothy Haystead)

Open Philanthropy recommended a grant of $14,355 to Duke University to enable Professor Timothy Haystead to collaborate with researchers at UC Davis and the Weill Cornell Medical College of Cornell University to study the effectiveness of an Hsp90 protein inhibitor as a host-directed antiviral against the COVID-19 virus.

This follows our May 2020 support for earlier phases of the study at Duke University and falls within our work on scientific research, specifically our interest in science supporting biosecurity and pandemic preparedness.

Georgia Tech — Research on Lipid Nanoparticles (James Dahlman)

Open Philanthropy recommended a grant of $882,000 over two years to Georgia Tech to support a collaboration between Professor James Dahlman and Professor Jeffrey Glenn, of Stanford University, to develop and test novel lipid nanoparticles for use in antiviral drug candidates intended to prevent infections by all beta-coronaviruses and influenza strains. Effective pan-influenza and -coronavirus antiviral drugs could avert hundreds of thousands of deaths annually and minimize the spread of highly infectious and lethal strains of the viruses.

This falls within our work on scientific research, specifically within our interest in science supporting biosecurity and pandemic preparedness.

Stanford University — Research on Lipid Nanoparticles (Jeffrey Glenn)

Open Philanthropy recommended a grant of $610,000 over two years to Stanford University to support a collaboration between Professor Jeffrey Glenn and Professor James Dahlman, of Georgia Tech, to develop and test novel lipid nanoparticles for use in antiviral drug candidates intended to prevent infections by all beta-coronaviruses and influenza strains. Effective pan-influenza and -coronavirus antiviral drugs could avert hundreds of thousands of deaths annually and minimize the spread of highly infectious and lethal strains of the viruses.

This follows our July 2020 support and falls within our work on scientific research, specifically within our interest in science supporting biosecurity and pandemic preparedness.

Binx — COVID-19 Testing Platform


Grant investigators: Heather Youngs and Chris Somerville

This page was reviewed but not written by the grant investigators. Binx staff also reviewed this page prior to publication.


Open Philanthropy recommended an investment of $2,000,000 in Binx to support work to incorporate Sherlock Biosciences’s COVID-19 assay into Binx’s point-of-care diagnostic platform. This funding is intended to support work to obtain Emergency Use Authorization approval of the Binx-Sherlock Biosciences COVID-19 testing platform.

This falls within our work on scientific research, specifically within our interest in advancing science supporting biosecurity and pandemic preparedness.